

Keywords:**Introduction**

Abstract

Introduction

Methods

Results

Conclusion

Adherence and tangible characteristics

Introduction

Methods

Results

Conclusion

.....

Conclusion

.....

Acknowledgments

.....

Conflict of Interest

.....

References

1. McLeod HL (1998) Clinically relevant drug-drug interactions in oncology. *Br J Clin Pharmacol* 45:539-544.
2. Ma J, Verweij J, Planting AS, Kolker HJ, Loos WJ, et al. (1996) Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes. *Cancer Chemother Pharmacol* 37:382-384.
3. Ando M, Saka H, Ando Y, Minami H, Kuzuya T, et al. (2005) Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences. *Cancer Chemother Pharmacol* 55:552-558.
4. Jiang S, Pan AW, Lin TY, Zhang H, Malfatti M, et al. (2015) Paclitaxel Enhances Carboplatin-DNA Adduct Formation and Cytotoxicity. *Chem Res Toxicol* 28:2250-2252.
5. Cadavid AP (2017) Aspirin: The Mechanism of Action Revisited in the Context of Pregnancy Complications. *Front Immunol* 8:261.
6. Pelkonen O, Pasanen M, Lindon JC, Chan K, Zhao L, et al. (2012) Omics and its potential impact on R&D and regulation of complex herbal products. *J Ethnopharmacol* 140:587-593.
7. Zhu X, Shen X, Qu J, Straubinger RM, Jusko WJ (2018) Multi-Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells. *CPT Pharmacometrics Syst Pharmacol* 7:549-561.
8. Wang X, Niu J, Li J, Shen X, Shen S, et al. (2018) Temporal Effects of Combined Birinapant and Paclitaxel on Pancreatic Cancer Cells Investigated via Large-Scale, Ion-Current-Based Quantitative Proteomics (IonStar). *Mol Cell Proteomics* 17:655-671.
9. Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. *Nat Med* 19, 1423–1437.
10. Jilek BL, Zarr M, Sampah ME, Rabi SA, Bullen CK, et al. (2012) A quantitative basis for antiretroviral therapy for HIV-1 infection. *Nat Med* 18:446-451.
11. Castiglione F, Pappalardo F, Bernaschi M, Motta S (2007) Optimization of HAART with genetic algorithms and agent-based models of HIV infection. *Bioinformatics* 23:3350-3355.
12. Huang SM, Temple R, Throckmorton DC, Lesko LJ (2007) Drug interaction studies: study design, data analysis, and implications for dosing and labeling. *Clin Pharmacol Ther* 81:298-304.
13. Barbaro G, Scozzafava A, Mastrolorenzo A, Supuran CT (2005) Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. *Curr Pharm Des* 11:1805-1843.